TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2029-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Central Nervous System (CNS) inflammation is an immune response activated in the brain and spinal cord by microglial cells and astrocytes, commonly occurring under conditions such as central nervous system ischemia, autoimmunity, infection, toxins, and trauma.

Microglial cells, as the innate immune cells of the central nervous system, are responsible for driving the inflammatory response and play a crucial role in sensing environmental changes, responding to harmful stimuli, and engulfing dead neurons. They also present antigens to T lymphocytes, mediating interactions between the peripheral immune system and the central nervous system. Factors released by neuronal cells can either promote or inhibit inflammation, and monitoring the level of inflammation driven by microglial cells is essential for the diagnosis and treatment of central nervous system diseases.

MRI is the primary imaging method for central nervous system inflammation, but it can be challenging to diagnose. PET/MR, a technology that integrates PET and MR imaging, provides high-quality diagnostic images and is valuable for the early detection, diagnosis, and assessment of central nervous system diseases. The radioactive ligand 18F-DPA-714 PET, targeting the translocation protein (TSPO), can visualize activated microglial cells, which may have a gain effect in detecting active central nervous system inflammation.

This study aims to explore the application of 18F-DPA-714 PET/MR in the early diagnosis, treatment evaluation, and prognosis of central nervous system inflammation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microglial Cells Activation Imaging Using PET-CT With 18F-DPA714

NCT04171882

Microglial Cells Activation Imaging

UNKNOWN

18F-DPA-714 PET/MR in Dysfunctional Brain Diseases

NCT06851143

Brain Disease

NOT_YET_RECRUITING NA

Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

NCT05293405

Autoimmune Encephalomyelitis

UNKNOWN NA

Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients

NCT06701734

Chroinc Pain PET Microglial Activation

NOT_YET_RECRUITING

Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

NCT02836327

Multiple Sclerosis Neuromyelitis Optica Spectrum Disorders

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICVD

ischemic cerebrovascular diseases

Radiation: PET-MRI with [18F]-DPA-714

Intervention Type RADIATION

Radiation: PET-MRI with \[18F\]-DPA-714

Neurological Autoimmune Diseases

Multiple Sclerosis，Neuromyelitis Optica Spectrum Disorders and Autoimmune Encephalitis

Radiation: PET-MRI with [18F]-DPA-714

Intervention Type RADIATION

Radiation: PET-MRI with \[18F\]-DPA-714

other

other encephalomyelitis

Radiation: PET-MRI with [18F]-DPA-714

Intervention Type RADIATION

Radiation: PET-MRI with \[18F\]-DPA-714

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation: PET-MRI with [18F]-DPA-714

Radiation: PET-MRI with \[18F\]-DPA-714

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Clinical diagnosis of ischemic stroke, autoimmune ecephalitis, Neuromyelitis optica spectrum disorders, or multiple sclerosis, etc.al

Exclusion Criteria

* Claustrophobia
* Metal Implants
* Pregancy
* Breast-feeding
* Renal insufficiency (GFR \< 60 mL/min/1.73m2)
* Allergy or other contraindication to gadolinium-based MR contrast agent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes